Approaches for enhancing the informativeness and quality of clinical trials: Innovations and principles for implementing multicenter trials from the Trial Innovation Network

被引:3
|
作者
Lane, Karen [1 ]
Palm, Marisha E. E. [2 ,3 ]
Marion, Eve [4 ]
Kay, Marie T. T. [5 ]
Thompson, Dixie [5 ]
Stroud, Mary [6 ]
Boyle, Helen [4 ]
Hillery, Shannon [7 ]
Nanni, Angeline [7 ]
Hildreth, Meghan [1 ]
Nelson, Sarah [8 ]
Burr, Jeri S. S. [5 ]
Edwards, Terri [6 ]
Poole, Lori [4 ]
Waddy, Salina P. P. [9 ]
Dunsmore, Sarah E. E. [9 ]
Harris, Paul [10 ]
Wilkins, Consuelo [11 ]
Bernard, Gordon R. R. [6 ]
Dean, J. Michael [5 ]
Dwyer, Jamie [5 ]
Benjamin, Daniel K. K. [4 ]
Selker, Harry P. P. [3 ,12 ,13 ]
Hanley, Daniel F. F. [14 ]
Ford, Daniel E. E. [15 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21218 USA
[2] Tufts Med Ctr, Boston, MA USA
[3] Tufts Med Ctr, Inst Clin Res, Hlth Policy Studies, Boston, MA USA
[4] Duke Univ, Duke Clin Res Inst, Sch Med, Durham, NC USA
[5] Univ Utah, Sch Med, Salt Lake City, UT USA
[6] Vanderbilt Univ, Vanderbilt Inst Clin & Translat Res, Med Ctr, Nashville, TN USA
[7] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[8] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[9] Natl Ctr Adv Translat Sci, Div Clin Innovat, Bethesda, MD USA
[10] Vanderbilt Univ Sch Med, Nashville, TN USA
[11] Vanderbilt Univ, Dept Med, Med Ctr, Nashville, TN USA
[12] Tufts Univ, Tufts Clin & Translat Sci Inst, Boston, MA USA
[13] Tufts Med Ctr, Hlth Policy Studies, Boston, MA USA
[14] Johns Hopkins Univ, Sch Med, Acute Care Neurol, Baltimore, MD USA
[15] Johns Hopkins Univ, Inst Clin & Translat Res, Sch Med, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
Multicenter trials; informative trials; Trial Innovation Network; study planning; clinical trial budgets; clinical trial resources;
D O I
10.1017/cts.2023.560
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
One challenge for multisite clinical trials is ensuring that the conditions of an informative trial are incorporated into all aspects of trial planning and execution. The multicenter model can provide the potential for a more informative environment, but it can also place a trial at risk of becoming uninformative due to lack of rigor, quality control, or effective recruitment, resulting in premature discontinuation and/or non-publication. Key factors that support informativeness are having the right team and resources during study planning and implementation and adequate funding to support performance activities. This communication draws on the experience of the National Center for Advancing Translational Science (NCATS) Trial Innovation Network (TIN) to develop approaches for enhancing the informativeness of clinical trials. We distilled this information into three principles: (1) assemble a diverse team, (2) leverage existing processes and systems, and (3) carefully consider budgets and contracts. The TIN, comprised of NCATS, three Trial Innovation Centers, a Recruitment Innovation Center, and 60+ CTSA Program hubs, provides resources to investigators who are proposing multicenter collaborations. In addition to sharing principles that support the informativeness of clinical trials, we highlight TIN-developed resources relevant for multicenter trial initiation and conduct.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Total quality management of clinical trial supplies (Reprinted from Drug Products for Clinical Trials, vol 87, pg 367-381, 1998)
    Barker, NP
    CLINICAL RESEARCH AND REGULATORY AFFAIRS, 2000, 17 (03) : 231 - 245
  • [22] Post-gene translational research: from mouse drug trials to an international human clinical trial network in Duchenne dystrophy.
    Escolar, D
    Henricson, E
    Granchelli, J
    Buyse, G
    Leshner, R
    Hoffman, EP
    AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (04) : 431 - 431
  • [23] A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study
    Yarchoan, Mark
    Cope, Leslie
    Anders, Robert A.
    Noonan, Anne
    Goff, Laura W.
    Goyal, Lipika
    Lacy, Jill
    Li, Daneng
    Patel, Anuj
    He, Aiwu R.
    Abou-Alfa, Ghassan
    Spencer, Kristen
    Kim, Edward
    Xavier, Stephanie
    Ruggieri, Amanda
    Davis, S. Lindsey
    McRee, Autumn
    Kunk, Paul
    Zhu, Qingfeng
    Wang-Gillam, Andrea
    Poklepovic, Andrew
    Chen, Helen
    Sharon, Elad
    Lesinski, Gregory B.
    Azad, Nilo
    CANCER RESEARCH, 2020, 80 (16)
  • [24] Do Treatment Improvements in PTSD Severity Affect Substance Use Outcomes? A Secondary Analysis From a Randomized Clinical Trial in NIDA's Clinical Trials Network
    Hien, Denise A.
    Jiang, Huiping
    Campbell, Aimee N. C.
    Hu, Mei-Chen
    Miele, Gloria M.
    Cohen, Lisa R.
    Brigham, Gregory S.
    Capstick, Carrie
    Kulaga, Agatha
    Robinson, James
    Suarez-Morales, Lourdes
    Nunes, Edward V.
    AMERICAN JOURNAL OF PSYCHIATRY, 2010, 167 (01): : 95 - 101
  • [25] Selective reporting bias in randomised controlled trials from two network meta-analyses: comparison of clinical trial registrations and their respective publications
    Wong, Eric K. C.
    Lachance, Chantelle C.
    Page, Matthew J.
    Watt, Jennifer
    Veroniki, Areti
    Straus, Sharon E.
    Tricco, Andrea C.
    BMJ OPEN, 2019, 9 (09):
  • [26] Cost-Effectiveness of Repair versus Replacement for Severe Ischemic Mitral Regurgitation: A Randomized Clinical Trial From the Cardiothoracic Surgical Trials Network
    Ferket, Bart S.
    Ailawadi, Gorav
    Gelijns, Annetine
    Acker, Michael A.
    Hohmann, Samuel F.
    Chang, Helena
    Bouchard, Denis
    Meltzer, David
    Michler, Robert E.
    Moquete, Ellen
    Voisine, Pierre
    Mullen, John C.
    Mack, Michael
    Gillinov, A. M.
    Thourani, Vinod
    Miller, Marissa A.
    Gammie, James
    Parides, Michael
    Bagiella, Emilia
    Smith, Robert L.
    Smith, Peter K.
    Hung, Judy W.
    Gupta, Lopa
    Rose, Eric A.
    O'Gara, Patrick
    Moskowitz, Alan
    CIRCULATION, 2016, 134
  • [27] Prediction of quality of life in schizophrenia using machine learning models on data from Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial
    Mélissa Beaudoin
    Alexandre Hudon
    Charles-Edouard Giguère
    Stéphane Potvin
    Alexandre Dumais
    Schizophrenia, 8
  • [28] Integrating Quality of Life and Survival Outcomes Cardiovascular Clinical Trials: Results From the PARTNER Trial (vol 12, e005420, 2019)
    Spertus
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2019, 12 (09):
  • [29] Prediction of quality of life in schizophrenia using machine learning models on data from Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial
    Beaudoin, Melissa
    Hudon, Alexandre
    Giguere, Charles-Edouard
    Potvin, Stephane
    Dumais, Alexandre
    SCHIZOPHRENIA, 2022, 8 (01)
  • [30] Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network
    Laport, Ginna G.
    Wu, Juan
    Logan, Brent
    Bachanova, Veronika
    Hosing, Chitra
    Fenske, Timothy
    Longo, Walter
    Devine, Steven M.
    Nademanee, Auayporn
    Gersten, Iris
    Horowitz, Mary
    Lazarus, Hillard M.
    Riches, Marcie L.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (08) : 1440 - 1448